The Medical Affairs Company (TMAC)
Medical Science Liaison, Oncology, Solid Tumor (West)
The Medical Affairs Company (TMAC), California, Missouri, United States, 65018
Overview
The Medical Affairs Company (TMAC) provides pay range below. Your actual pay will be based on your skills and experience — talk with your recruiter to learn more. Base pay range $180,000.00/yr - $200,000.00/yr Direct message the job poster from The Medical Affairs Company (TMAC). Senior Recruiter @ The Medical Affairs Company | Global Talent Acquisition
Territory coverage:
CA, CO, OR, WA, NM The MSL will initially support the Company’s lead product candidate, an orally available small molecule for the treatment of patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. The US FDA has granted Fast Track designation for the treatment of cancer patients with locally advanced or metastatic solid tumors that have this mutation. The MSL will be a field-based extension of Medical Affairs, representing the Company and building long-term, credible, peer-to-peer relationships through scientific/medical exchange with clinicians, investigators, thought leaders, and other stakeholders in Oncology. The MSL will support the Company’s advancing clinical and research programs, delivering clinical, scientific, and technical education to the Oncology community. The MSL will cultivate and maintain collaborative relationships to advance disease-state and therapeutic awareness and advocacy and will serve as a technical, scientific, and medical expert to the Oncology community for the assigned region.
#J-18808-Ljbffr
The Medical Affairs Company (TMAC) provides pay range below. Your actual pay will be based on your skills and experience — talk with your recruiter to learn more. Base pay range $180,000.00/yr - $200,000.00/yr Direct message the job poster from The Medical Affairs Company (TMAC). Senior Recruiter @ The Medical Affairs Company | Global Talent Acquisition
Territory coverage:
CA, CO, OR, WA, NM The MSL will initially support the Company’s lead product candidate, an orally available small molecule for the treatment of patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. The US FDA has granted Fast Track designation for the treatment of cancer patients with locally advanced or metastatic solid tumors that have this mutation. The MSL will be a field-based extension of Medical Affairs, representing the Company and building long-term, credible, peer-to-peer relationships through scientific/medical exchange with clinicians, investigators, thought leaders, and other stakeholders in Oncology. The MSL will support the Company’s advancing clinical and research programs, delivering clinical, scientific, and technical education to the Oncology community. The MSL will cultivate and maintain collaborative relationships to advance disease-state and therapeutic awareness and advocacy and will serve as a technical, scientific, and medical expert to the Oncology community for the assigned region.
#J-18808-Ljbffr